Company Overview
Snapshot
Founded in June 2019 by Gil Shapira and Moshe Eshkol, Squalus Medical operates with 1–10 employees. The company has raised $1 million across one funding round. In January 2021, the company received a grant from the BIRD Foundation.
Business overview
Squalus Medical is developing a laser-based thermal ablation technology designed to treat previously inoperable cases of epilepsy and enhance the outcomes of existing procedures. Their core product, the StingRay Laser System, integrates fiber-optic technology with an advanced laser console. This system is engineered to precisely match the epileptic focal source and energy delivery, while safeguarding vital functional areas from thermal damage. The console also features computer-vision analysis to guide physicians, ensuring treatments are tailored to individual patients and meet preplanned clinical requirements. Squalus Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.
Strategic signal
In January 2021, Squalus Medical received a grant from the BIRD Foundation, indicating external validation and support for its innovative laser-based thermal ablation technology for epilepsy treatment. This grant signals confidence in the company's R&D efforts and its potential to address unmet needs in neurological care, suggesting a positive trajectory for product development and market entry.
Log in to access full profile ›Company Intelligence Q&A
- What is Squalus Medical's primary focus?
- Squalus Medical is developing a laser-based thermal ablation technology for treating epilepsy, particularly for cases that were previously considered inoperable, and to improve the outcomes of current procedures.
- When was Squalus Medical founded and by whom?
- Squalus Medical was founded in June 2019 by Gil Shapira and Moshe Eshkol.
- What is the StingRay Laser System?
- The StingRay Laser System is Squalus Medical's core product, combining fiber-optic technology with an advanced laser console that precisely targets epileptic focal sources and delivers energy while protecting vital functional areas. It also integrates computer-vision for physician guidance.
- Has Squalus Medical received any grants?
- In January 2021, Squalus Medical received a grant from the BIRD Foundation, which was part of a larger investment of $7.45 million across eight new projects.
- What is Squalus Medical's current product development stage?
- Squalus Medical's StingRay Laser System is currently in the R&D product stage, focusing on developing its laser-based thermal ablation system for epilepsy treatment.